高级检索
当前位置: 首页 > 详情页

The prognostic value of preoperative neutrophil-to-lymphocyte ratio in patients with upper tract urothelial carcinoma.

文献详情

资源类型:
Pubmed体系:
机构: [1]Department of Urology & Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, China [2]Department of Pathology, West China Hospital, Sichuan University, Chengdu, China [3]Department of Molecular and Medical Pharmacology, University of California, Los Angeles, CA, United States
出处:
ISSN:

关键词: Neutrophil-lymphocyte ratio Tumor grade Upper urinary tract Urothelial carcinoma Prognosis

摘要:
We evaluated the prognostic impact of the preoperative neutrophil-to-lymphocyte ratio (NLR) in patients with upper tract urothelial carcinoma (UTUC) after radical nephroureterectomy treatment. A total of 717 patients were identified between 2003 and 2016. The cutoff value of NLR was set as 2.5. Kaplan-Meier method and Cox's proportional hazards regression models were utilized to analyze the association between NLR and oncological outcomes. The median follow-up was 42 months. The results suggested that preoperative elevated NLR was associated with worse pathological features. Also, patients with NLR ≥ 2.5 had worse survival outcomes than those with NLR <2.5 (all P < .001). Multivariate cox analysis revealed that NLR ≥ 2.5 was an independent predictor of worse cancer-specific survival, disease recurrence-free survival, metastasis-free survival and overall survival (HR 1.95, 95%CI: 1.42-2.69, P < .001; HR 1.70, 95%CI: 1.31-2.20, P < .001; HR 1.67, 95%CI: 1.22-2.31, P = .002; and HR 1.88, 95%CI: 1.42-2.50, P < .001; respectively). Notably, NLR was ascertained to be a useful prognostic predictor in patients with high-grade disease, but not in those with low-grade UTUC. Preoperative elevated NLR was associated with worse outcomes in patients with UTUC. Subgroup analysis affirmed that NLR was a useful predictor in patients with high-grade disease, but not in those with low-grade UTUC. Copyright © 2018 Elsevier B.V. All rights reserved.

基金:
语种:
PubmedID:
中科院(CAS)分区:
出版当年[2018]版:
大类 | 3 区 医学
小类 | 2 区 医学实验技术
最新[2023]版:
大类 | 3 区 医学
小类 | 3 区 医学实验技术
第一作者:
第一作者机构: [1]Department of Urology & Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, China
共同第一作者:
通讯作者:
通讯机构: [*1]Department of Urology & Institute of Urology, West China Hospital, Sichuan University, Number 37, Guoxue Alley, Chengdu, Sichuan 610041, China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:43377 今日访问量:0 总访问量:3120 更新日期:2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号